BlossomHill Therapeutics, Inc. - 10-Q Filing
BlossomHill Therapeutics reports Q3 2026 results with focus on R&D for BH-30643, BH-30236, and BH-501284 candidates.
Tickers: $BLSM
BlossomHill Therapeutics reports Q3 2026 results with focus on R&D for BH-30643, BH-30236, and BH-501284 candidates.
Tickers: $BLSM